Trial · NCT05168813
Participant flow90
How many started, completed or left each group, period by period.
61 to 80 of 90
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part B (Blinded) | Safety Set (SS) | Part A (Open-label): Study Group 1 | 0 | |
| Part B (Blinded) | Safety Set (SS) | Part A (Open Label): Study Group 2 | 0 | |
| Part B (Blinded) | Safety Set (SS) | Part A (Open-label): Study Group 3 | 0 | |
| Part B (Blinded) | Safety Set (SS) | Part A (Open-label): Study Group 4 | 0 | |
| Part B (Blinded) | Safety Set (SS) | Part B (Blinded): mRNA-1273 at Month 6 | 1,323 | |
| Part B (Blinded) | Safety Set (SS) | Part B (Blinded): mRNA-1273.222 at Month 6 | 89 | |
| Part B (Blinded) | Immunogenicity Set (IS) | Part A (Open-label): Study Group 1 | 0 | |
| Part B (Blinded) | Immunogenicity Set (IS) | Part A (Open Label): Study Group 2 | 0 | |
| Part B (Blinded) | Immunogenicity Set (IS) | Part A (Open-label): Study Group 3 | 0 | |
| Part B (Blinded) | Immunogenicity Set (IS) | Part A (Open-label): Study Group 4 | 0 | |
| Part B (Blinded) | Immunogenicity Set (IS) | Part B (Blinded): mRNA-1273 at Month 6 | 252 | |
| Part B (Blinded) | Immunogenicity Set (IS) | Part B (Blinded): mRNA-1273.222 at Month 6 | 26 | |
| Part B (Blinded) | Full Per-Protocol Set (FPP) | Part A (Open-label): Study Group 1 | 0 | |
| Part B (Blinded) | Full Per-Protocol Set (FPP) | Part A (Open Label): Study Group 2 | 0 | |
| Part B (Blinded) | Full Per-Protocol Set (FPP) | Part A (Open-label): Study Group 3 | 0 | |
| Part B (Blinded) | Full Per-Protocol Set (FPP) | Part A (Open-label): Study Group 4 | 0 | |
| Part B (Blinded) | Full Per-Protocol Set (FPP) | Part B (Blinded): mRNA-1273 at Month 6 | 1,960 | |
| Part B (Blinded) | Full Per-Protocol Set (FPP) | Part B (Blinded): mRNA-1273.222 at Month 6 | 2,002 | |
| Part B (Blinded) | COMPLETED | Part A (Open-label): Study Group 1 | 0 | |
| Part B (Blinded) | COMPLETED | Part A (Open Label): Study Group 2 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05168813/flow?page=4